MiMedx is a top growth pick for 2014 at Canaccord Canaccord named MiMedx a top growth pick for 2014 to reflect recent reimbursement changes, regulatory clarity on micronized products, Medtronic distribution agreement opportunity, and the positive coverage decision from the 6th MAC. Shares are Buy rated with a $12 price target raised from $8.
News For MDXG From The Last 14 Days
Check below for free stories on MDXG the last two weeks.
MiMedx reports Q1 revenue slightly exceeded upper end of guidance Q1 guidance was $18M-$19.5M. Q1 consensus of $19.09M. March revenue, in particular, grew significantly. The company expects a minimal amount of the confusion experienced in the first quarter will continue for a portion of the second quarter and then dissipate during the second quarter.